Protalix CEO granted 320K options, 160K RSUs

The president and CEO of PLX received new stock options and RSUs that vest quarterly, adding to his existing option holdings.

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) reported that its president and CEO, Dror Bashan, received equity-based compensation on September 3, 2026. He was granted 320,000 stock options to buy common stock at an exercise price of $2.59 per share, expiring on September 3, 2036, vesting in 12 equal quarterly installments beginning on the grant date, with potential accelerated vesting upon a corporate transaction or change in control under the company’s Amended and Restated 2006 Stock Incentive Plan. He was also granted 160,000 restricted stock units, each representing the right to receive one share of common stock after vesting, which also occurs in 12 equal quarterly installments beginning on the grant date. Following these grants, he holds 320,000 of these new options and 160,000 of these RSUs directly, and he also continues to hold previously granted options for 160,000 shares at $4.69 (expiring June 30, 2029), 750,000 shares at $1.03 (expiring September 7, 2032), and 340,000 shares at $1.64 (expiring September 3, 2035). No Rule 10b5-1 trading plan is reported for these awards.

Insider Trade Summary

Grant/Award: 480,000 shares

Grant/Award 2 txns

Insider Bashan Dror

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	320,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F3, F4	160,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 320,000 contracts (Direct); Restricted Stock Units — 160,000 contracts (Direct)

Footnotes (4)

1. F1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan.
2. F2. Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
3. F3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
4. F4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Key Figures

New stock options granted: 320,000 options New option exercise price: $2.59 per share New option expiration date: September 3, 2036 +5 more

8 metrics

New stock options granted 320,000 options Granted to the president and CEO on September 3, 2026

New option exercise price $2.59 per share Exercise price for 320,000 options granted September 3, 2026

New option expiration date September 3, 2036 Expiration for 320,000 options granted to the CEO

New RSUs granted 160,000 RSUs Restricted stock units granted to the CEO on September 3, 2026

Vesting schedule length 12 quarterly installments Applies to both the new options and RSUs, starting on grant date

Existing options at $4.69 160,000 options Existing options expiring June 30, 2029 at $4.69 per share

Existing options at $1.03 750,000 options Existing options expiring September 7, 2032 at $1.03 per share

Existing options at $1.64 340,000 options Existing options expiring September 3, 2035 at $1.64 per share

Key Terms

Restricted Stock Units, accelerated vesting, corporate transaction, change in control, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

accelerated vesting financial

"The stock options are subject to accelerated vesting upon a corporate transaction or a change"

A contract feature that makes stock awards, options, or restricted shares become owned or exercisable earlier than the original schedule. It shortens or cancels the waiting period so recipients can sell, transfer, or exercise their equity sooner — think of a timed lock that is unlocked ahead of schedule. It matters to investors because it changes when shares enter the market, who controls them, and how much dilution or ownership concentration happens.

corporate transaction financial

"subject to accelerated vesting upon a corporate transaction or a change in control"

change in control financial

"subject to accelerated vesting upon a corporate transaction or a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Amended and Restated 2006 Stock Incentive Plan financial

"as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan"

FAQ

What new equity awards did PLX grant to its CEO Dror Bashan on September 3, 2026?

On September 3, 2026, Dror Bashan received 320,000 stock options with a $2.59 exercise price expiring September 3, 2036, and 160,000 restricted stock units, each convertible into one share of common stock after vesting.

How do the new PLX stock options and RSUs granted to the CEO vest?

Both the 320,000 stock options and the 160,000 RSUs granted to the PLX CEO vest in 12 equal quarterly installments beginning on the grant date, meaning portions vest every quarter over three years.

What additional vesting protection applies to the new PLX stock options granted to the CEO?

The new stock options are subject to accelerated vesting upon a corporate transaction or change in control, as described in Protalix BioTherapeutics, Inc.’s Amended and Restated 2006 Stock Incentive Plan.

What prior option holdings does the PLX CEO have in addition to the new grants?

In addition to the new awards, the CEO holds options for 160,000 shares at $4.69 expiring June 30, 2029, 750,000 shares at $1.03 expiring September 7, 2032, and 340,000 shares at $1.64 expiring September 3, 2035.

Were the new PLX CEO equity grants made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with these September 3, 2026 stock option and RSU grants to the PLX CEO.

What does each restricted stock unit granted to the PLX CEO represent?

Each restricted stock unit granted to the PLX CEO represents the right to receive, after vesting, one share of Protalix BioTherapeutics, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:04 AM Accepted by SEC EDGAR 09/04/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bashan Dror

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	09/03/2026		A		320,000		(1)	09/03/2036	Common Stock	320,000	$0	320,000(2)	D
Restricted Stock Units	(3)	09/03/2026		A		160,000		(4)	(4)	Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan.

2. Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029, (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

	/s/ Joseph R. Magnas, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)